Key Points
- CEO Vishwas Seshadri sold 69,832 shares on Jan. 22 at an average price of $5.33 for about $372,205, reducing his stake by 4.56% to 1,460,408 shares; he also sold 25,000 shares on Dec. 29 at $5.31.
- Abeona shares trade around $5.36 with a market cap of roughly $290.5M and a 52-week range of $3.93–$7.54, while analysts have an average target of $20 and an average rating of "Moderate Buy" (four Buys, one Sell).
- The company is a clinical-stage gene and cell therapy developer with lead AAV and ex vivo programs, and institutional investors own about 80.56% of the stock.
Abeona Therapeutics Inc. (NASDAQ:ABEO - Get Free Report) SVP Brendan O'malley sold 13,578 shares of the company's stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $5.33, for a total transaction of $72,370.74. Following the completion of the transaction, the senior vice president owned 451,134 shares in the company, valued at approximately $2,404,544.22. This trade represents a 2.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
Abeona Therapeutics Trading Up 0.9%
Shares of Abeona Therapeutics stock opened at $5.36 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 9.74 and a quick ratio of 9.53. Abeona Therapeutics Inc. has a 1 year low of $3.93 and a 1 year high of $7.54. The firm has a market cap of $290.46 million, a PE ratio of 4.36 and a beta of 1.12. The company has a 50 day simple moving average of $5.07 and a two-hundred day simple moving average of $5.64.
Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last posted its quarterly earnings data on Wednesday, November 12th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.17. Analysts expect that Abeona Therapeutics Inc. will post -1.16 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
A number of research firms have recently issued reports on ABEO. HC Wainwright reiterated a "buy" rating and issued a $20.00 price objective on shares of Abeona Therapeutics in a report on Monday, October 13th. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Abeona Therapeutics in a research note on Wednesday. Finally, Wall Street Zen downgraded shares of Abeona Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, November 15th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Abeona Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $20.00.
Read Our Latest Research Report on Abeona Therapeutics
Institutional Trading of Abeona Therapeutics
Institutional investors have recently made changes to their positions in the stock. Intech Investment Management LLC grew its holdings in shares of Abeona Therapeutics by 19.6% in the third quarter. Intech Investment Management LLC now owns 25,176 shares of the biopharmaceutical company's stock worth $133,000 after purchasing an additional 4,127 shares during the last quarter. Creative Planning boosted its position in Abeona Therapeutics by 43.0% during the 2nd quarter. Creative Planning now owns 14,310 shares of the biopharmaceutical company's stock valued at $81,000 after buying an additional 4,305 shares during the period. Ameritas Investment Partners Inc. bought a new stake in Abeona Therapeutics in the 2nd quarter worth $25,000. Legal & General Group Plc purchased a new position in shares of Abeona Therapeutics in the second quarter valued at about $27,000. Finally, Riverwater Partners LLC raised its stake in shares of Abeona Therapeutics by 45.6% during the third quarter. Riverwater Partners LLC now owns 15,857 shares of the biopharmaceutical company's stock valued at $84,000 after acquiring an additional 4,963 shares during the last quarter. Hedge funds and other institutional investors own 80.56% of the company's stock.
About Abeona Therapeutics
(
Get Free Report)
Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company's research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.
The company's lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
